Author:
Dimitrijevic M.,Bartlett R. R.
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Bartlett RR, Schleyerbach R. Immunopharmacological profile of a novel isoxazol derivate, HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharm 1985;7:7–18.
2. Bartlett RR, Dimitrijevic M, Mattar T, Zielinski T, Germann T, Rude E, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of auto-immune disorders and reactions leading to transplantation rejection. Agents Actions 1991;32:10–21.
3. Ogawa T, Inazu M, Gotoh K, Hayashi S. Effects of leflunomide on glomerulonephritis induced by antibasement membrane antibody in rats. Agents Actions 1990;31:321–8.
4. Smith-Long L, Glaser B, Weimer LK, Miller ST, Robertson SM, Aoki KR, et al. Efficacy of novel immunomodulators leflunomide and rapamycin in autoimmune uveitis. FASEB J 1992;6:A1048.
5. Xiao F, Chong AS-F, Bartlett RR, Williams JW, Leflunomide: a promising immunosuppressant in transplantation. In: Thompson AW, Starzl TE, editors. Immunosuppressive Drugs. Developments in anti-rejection therapy. London: Edward Arnold, 1994;203–12.
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献